Importing Medical Cannabis to the UK: A Regulatory Guide

The Legal Framework for Cannabis Imports

• Medical cannabis imports require a controlled drug import licence from the Home Office
• Each consignment typically requires a separate import licence application
• The exporting country must also authorise the export under its own controlled drug legislation
• Import licences specify the product, quantity, origin, and permitted timeframe

Importing medical cannabis into the United Kingdom involves navigating a dual regulatory landscape: the controlled drug licensing regime administered by the Home Office, and the medicinal product requirements overseen by the MHRA. Both sets of obligations must be satisfied simultaneously, and failure on either front can delay or prevent product reaching patients.

Wholesale Dealer Authorisation Requirements

• All importers of unlicensed medicinal cannabis must hold a Wholesale Dealer’s Authorisation from the MHRA
• The WDA application requires evidence of GDP-compliant premises and qualified persons
• A Responsible Person must be designated with appropriate pharmaceutical qualifications
• MHRA conducts pre-authorisation inspections of import and storage facilities

The Wholesale Dealer’s Authorisation is the gateway licence for legitimate medical cannabis importers in the UK. Obtaining it requires demonstrating compliance with Good Distribution Practice across the entire import operation — from receipt at the UK border through to supply to dispensing pharmacies. Building these systems before applying is essential; the MHRA will inspect before granting the authorisation.

EU-GMP Certification and Source Requirements

• Cannabis cultivated for medical use must be produced at EU-GMP certified facilities
• EU-GMP certificates must be current and cover the specific product categories being imported
• The MHRA currently recognises EU-GMP certificates issued under EMA oversight
• Product must be accompanied by a Certificate of Analysis from an accredited laboratory

Sourcing EU-GMP certified cannabis is a fundamental requirement of the UK import pathway. The EU-GMP framework provides assurance that products have been manufactured under consistently controlled conditions with full traceability from seed to finished product. Importers should conduct thorough due diligence on cultivator credentials and maintain up-to-date copies of all certification documentation.

Practical Steps for New Importers

• Appoint a Responsible Person with an appropriate pharmaceutical background early in the process
• Identify and qualify GDP-compliant storage facilities before applying for authorisations
• Establish relationships with EU-GMP certified cultivators and agree supply agreements
• Engage specialist regulatory consultants familiar with both MHRA and Home Office requirements

The process of becoming an authorised medical cannabis importer in the UK is lengthy and resource-intensive. Companies that approach it systematically — sequencing licence applications correctly, building compliant infrastructure in advance, and engaging regulatory expertise — are far better placed than those who try to proceed without adequate preparation. The investment in doing it properly is justified by the long-term commercial opportunity.